Kiwi (Act d 2) IgE

If you've ever had your lips tingle after biting into kiwi, broken out in hives, or had a more serious reaction, the obvious question is: what exactly in the fruit is your body reacting to? This test answers part of that question by zeroing in on the IgE antibodies your immune system makes against a single kiwi protein called Act d 2, a member of a family known as thaumatin-like proteins.

Knowing your sensitization to Act d 2 (a specific kiwi allergen) helps refine the picture beyond a standard kiwi extract test. It is one piece of a larger molecular puzzle that allergists use to figure out whether your reaction is likely to be mild, severe, driven by pollen cross-reactivity, or a true primary kiwi allergy.

What This Test Actually Measures

This test measures IgE (immunoglobulin E, the antibody class your body makes during allergic reactions) directed at one specific kiwi protein. Whole kiwi fruit contains many proteins, and a standard kiwi IgE test lumps them all together. This test isolates Act d 2, which belongs to a family called thaumatin-like proteins, found in many plant foods.

A positive result tells you your immune system has learned to recognize this particular protein. It does not, on its own, tell you whether you will react when you eat kiwi, or how severe that reaction would be. That distinction matters and shapes how the result should be interpreted.

Where Act d 2 Sits in the Bigger Picture

Kiwi contains several proteins that can trigger allergy, labeled Act d 1 through Act d 13. Each one tells a different story about your allergy. Act d 1 (actinidin, an enzyme in kiwi) tends to be the marker most associated with isolated, sometimes more severe kiwi allergy. Act d 8 is a birch pollen homologue and usually reflects cross-reactivity with birch, while Act d 9 is a profilin that points more broadly to cross-reactivity with grass and other pollens. In both cases, your reaction may be a downstream effect of pollen sensitization rather than a primary food allergy.

Act d 2 sits in its own category. It is a thaumatin-like protein, and its clinical importance depends on the testing platform and study population. On some platforms and in some cohorts, Act d 2 is recognized by the majority of kiwi-allergic patients and is considered a major allergen. In the largest recent multiplex-based study, by contrast, sensitization to Act d 2 was uncommon and, when it appeared in isolation, often clinically quiet. When it appeared alongside other plant allergen sensitivities, more significant reactions occurred.

How Common Sensitization Actually Is

In a large Italian cohort of 7,176 allergic patients tested on a multiplex platform, sensitization to thaumatin-like proteins (mostly Act d 2) occurred in only 1.9%. Among the people who tested positive only to thaumatin-like proteins and nothing else, IgE levels averaged about 0.6 kUA/L (a small concentration of the antibody), and symptoms were minimal.

People who were co-sensitized to other plant panallergens had higher antibody levels averaging about 1.4 kUA/L, and more reactions including oral allergy syndrome (itching and tingling in the mouth after eating certain foods) and food-dependent exercise-induced anaphylaxis (a serious whole-body reaction that occurs only when a food is eaten before exercise). The pattern of what else you react to matters as much as the kiwi result itself.

What the Number Predicts About Severity

A central question is whether a higher Act d 2 IgE means a worse reaction. The honest answer, based on current evidence, is that it does not predict severity well. A formal analysis in the Italian cohort showed that Act d 2 IgE had only a 0.51 to 0.61 chance of correctly distinguishing severe from mild reactors, where 1.0 would be perfect and 0.5 would be the same as a coin flip.

After adjusting for other factors, Act d 2 IgE was not independently linked to moderate or severe symptoms. Translation: a single Act d 2 number, in isolation, is a sensitization marker, not a severity gauge. To gauge severity, your allergist will combine this result with your history, other component results, and sometimes a supervised food challenge.

Reconciling a Confusing Pattern

You may encounter a result that seems contradictory: a positive Act d 2 IgE alongside no symptoms when you eat kiwi, or symptoms with a negative Act d 2 result. Both are common. Sensitization simply means your immune system has produced the antibody; clinical allergy requires that the antibody actually trigger a reaction when you encounter the food. Many people are sensitized without being allergic.

In one smaller adult cohort tested on a multiplex platform, Act d 2 IgE correctly identified zero of the patients with clinical kiwi symptoms, while still being highly specific. Most clinically reactive patients in that group were Act d 2 negative. The takeaway is that Act d 2 alone, especially on certain platforms, is neither sufficient to diagnose kiwi allergy nor sufficient to rule it out.

Connection to Baker's Asthma

There is one occupational link worth knowing. Among 20 patients with baker's asthma (a lung condition that develops from breathing wheat flour at work), 35% developed oral allergy syndrome to kiwi, and 43% of those kiwi-allergic bakers had detectable IgE to Act d 2.

Investigation suggested the cross-reactivity was driven by sugar structures shared across plants and thiol-protease enzymes related to Act d 1 in wheat, rather than Act d 2 itself. So Act d 2 may flag the broader allergic profile, even if it is not the direct cause of the reaction.

Why One Reading Is Not Enough

Sensitization can change over time, especially in children, who may outgrow some food allergies and develop others. Even in adults, your antibody profile can shift in response to ongoing pollen exposure or changes in diet. A single Act d 2 result is a snapshot, not a trajectory.

As a general matter of allergy practice (not a recommendation specific to Act d 2), if you are tracking a known sensitization or wondering whether tolerance is developing, repeat testing every 1 to 2 years is reasonable. If you are starting any form of allergen avoidance or considering supervised food reintroduction with an allergist, a follow-up in 6 to 12 months gives a more accurate read on whether your immune response is changing. Whatever single result you get matters less than what happens to that number over time.

What to Do With an Unexpected Result

If your Act d 2 IgE comes back positive but you eat kiwi without symptoms, do not start avoiding the fruit based on the number alone. Sensitization without clinical reactivity is common, and unnecessary food avoidance can narrow your diet without benefit. If your number is positive and you do react to kiwi, the result confirms a sensitization pattern but does not predict whether your next reaction will be the same severity as your last.

A more useful workup is to pair this test with the other kiwi components, especially Act d 1, Act d 5, Act d 8, Act d 9, and Act d 10, to see whether your sensitization is primary or cross-reactive. An allergist may also recommend a prick-by-prick skin test using fresh kiwi, which has higher sensitivity than blood testing alone. In cases where the picture remains unclear and the question matters (such as for a child with limited exposure), a supervised oral food challenge remains the most definitive answer.

When Results Can Be Misleading

A few situations can make a single Act d 2 result harder to interpret. First, cross-reactive sugar structures on plant proteins can produce positive IgE results that do not reflect a true allergic threat to kiwi. Second, the specific lab method used affects sensitivity. Multiplex platforms that test many allergens at once can miss Act d 2 sensitization that a single-allergen assay would catch, and vice versa, which may also explain why some studies classify Act d 2 as a major allergen while others find it uncommon.

• Cross-reactive sugars: plant proteins share sugar tags that can trigger positive IgE without clinical relevance; an allergist can run a specific test to check for this.
• Assay platform differences: results from one multi-allergen panel may not match results from a different platform, so comparisons across labs require care.
• Recent allergen exposure: ongoing exposure to related pollens can shift component IgE patterns over weeks to months.
• Total IgE elevation: people with very high overall IgE from atopic conditions can have low-level positive results across many components that do not reflect true clinical allergy.